QBW 251

Drug Profile

QBW 251

Alternative Names: NVP-QBW-251; QBW251

Latest Information Update: 08 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Class Antifibrotics
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease; Cystic fibrosis

Most Recent Events

  • 05 Apr 2017 Novartis plans regulatory filings for Cystic fibrosis in 2021
  • 29 Feb 2016 Novartis terminates a phase II trial in Cystic fibrosis in USA, Belgium, France, Germany, Ireland, Romania and the United Kingdom (NCT02190604)
  • 12 Jun 2015 Phase-II clinical trials in Chronic obstructive pulmonary disease in USA (PO) (NCT02449018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top